Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320–Mediated Suppression of the Androgen Receptor

Abstract

Targeting androgen receptor (AR) by pharmacologic intervention is one of the effective approaches for treatment of malignant prostate cancers. Histone deacetylase (HDAC) alters the epigenetic status of tumor-associated genes, including those for miRNAs (miRNA), and affects the behavior of cancers. Here, we examined the molecular effects of a HDAC inhibitor, OBP-801, on AR expression and tumor cell growth in prostate cancers. Treatment with OBP-801 efficiently suppressed cell growth of three prostate cancer lines (22Rv1, VCaP, and LNCaP), together with AR downregulation, regardless of their hormone sensitivity. Intriguingly, this effect by OBP-801 was not due to decreased transcriptional activity of the AR gene, but due to posttranscriptional regulation, namely by miRNA-mediated suppression. Among the upregulated miRNAs after OBP-801 treatment in the three prostate cancer cell lines, miR-320a, whose expression was significantly correlated with prognosis of prostate cancers (P ¼ 0.0185), was the most closely associated with AR expression. An miR-320a mimic suppressed AR protein expression together with growth suppression, while anti-miR-320a oligonucleotide significantly abrogated the growth suppression by OBP-801 treatment. FISH analysis revealed that miR-320a was highly expressed in human normal prostate luminal cells, but was rarely expressed in prostate cancer cells. In an AR-dependent prostate tumorigenic rat model, OBP-801 treatment profoundly increased miR-320a expression and repressed prostate tumorigenesis. Our data demonstrated that OBP-801 effectively suppressed AR activity via epigenetic upregulation of miR-320a, which resulted in tumor cell growth suppression of prostate cancers. OBP-801 may be a potent AR-targeting therapeutic reagent in AR-positive prostate cancer regardless of androgen dependency. Cancer Res; 76(14); 4192-204. Ó2016 AACR.

Prostate Cancer Patients–Negative Biopsy Controls Discrimination by Untargeted Metabolomics Analysis of Urine by LC-QTOF: Upstream Information on Other Omics

“…Sato et al . proved that the inhibition of histone deacetylase efficiently suppressed cell growth of three prostate cancer lines together with down-regulation of the androgen receptor, regardless of their hormone sensitivity, based on miRNA-mediated suppression26.…”

MicroRNA‐320a inhibits invasion and metastasis in osteosarcoma by targeting cytoplasmic polyadenylation element‐binding protein 1

“…miR‐320a is encoded in the antisense orientation of the cell cycle gene POLR3D and plays a critical role in transcriptional silencing expression of POLR3D . Many studies have proved that miR‐320a could inhibit cell proliferation, induces apoptosis, affect cell cycle and plays a critical role of anti‐tumor in many cancers . However, the relationship between expression of miR‐320a and osteosarcoma progression remains unclear .…”

Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas

“…Additionally, miR-320a has been observed to be an independent prognostic factor where decreased miR-320a expression is correlated with lower survival in invasive breast cancer. [32] The anti-proliferative and tumor-suppressing effects of miR-320a have also been recorded in lung cancer [33], prostate cancer [34], gastric cancer [35], leukemia [36, 37], and nasopharyngeal carcinoma [38]. …”